HeartBeam (BEAT) announced that the first patients have been enrolled in its ALIGN-ACS pilot study evaluating the HeartBeam System for heart attack detection. The first patients were enrolled by Vladan Vukcevic at the University Clinical Center of Serbia in Belgrade, Serbia.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BEAT:
- HeartBeam: Commercial Partnership and FDA-Cleared ECG Platform Underpin Long-Term Growth and Buy Rating
- HeartBeam (NASDAQ: BEAT) Announces Commercial Partnership With ClearCardio
- HeartBeam announces investment from, partnership with ClearCardio
- HeartBeam (NASDAQ: BEAT) Upgraded to Buy as New Joseph Gunnar Report Raises Price Target
- HeartBeam (NASDAQ: BEAT) Showcased for Advancing Innovative ECG Platform